FOLH1 and prostate cancer: Currently, the focus of theranostics is increasingly directed to neuroendocrine tumors, by leveraging the high levels of somatostatin receptor (SSTR) expression, conjugating a peptide that binds to the receptor with a radionuclide, forming Lu-DOTATATE, and in prostate cancer, by employing the prostate-specific membrane antigen (PSMA), conjugated with Lutetium-177 (Lu-PSMA) [7,8,9].